# Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

> **NCT02620423** · PHASE1 · COMPLETED · sponsor: **Oncolytics Biotech** · enrollment: 11 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **BIOLOGICAL:** REOLYSIN®
- **DRUG:** Chemotherapy
- **DRUG:** Gemcitabine
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02620423
- **Lead sponsor:** Oncolytics Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-03
- **Final completion:** 2018-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620423, "Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02620423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*